drugset / Trial / NCT04818099

Vortioxetine in the Treatment of Depression Associated With Head and Neck Cancers Undergoing Radiotherapy

NCT04818099

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the effects of vortioxetine, once daily (QD), on mood disorders and cognitive dysfunction in patients with head and neck cancers undergoing radiotherapy.

Timeline

Start
2020-10-10
Primary completion
2023-10-10
Completion
2024-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Vortioxetine Unknown 10 mg